Further, because they can be harvested from the patients themselves, there is no fear of any adverse immune response as there is with embryonic stem cells.
The long timelines for drug development stem from a large number of factors, but one of the key reasons is that the FDA, largely in response to major drug problems with drugs like Rezulin and the Cox-2 inhibitors, has required larger and longer trials.